tetano
Editor, Senior Moderator
Influenza Other Respir Viruses
. 2023 Jan;17(1):e13079.
doi: 10.1111/irv.13079.
Investigating the transmission of baloxavir-resistant influenza viruses from treated index patients to untreated household contacts in the BLOCKSTONE study
Joanne Harding[SUP] 1 [/SUP], Corrado Bernasconi[SUP] 2 [/SUP], Sarah Williams[SUP] 1 [/SUP], Steffen Wildum[SUP] 2 [/SUP], Masahiro Kinoshita[SUP] 3 [/SUP], Takeki Uehara[SUP] 3 [/SUP], Aeron C Hurt[SUP] 2 [/SUP]
Affiliations
Abstract
In a post-hoc analysis of the phase 3 BLOCKSTONE study (JapicCTI-184180), we investigated household transmission of baloxavir-resistant (PA/I38X) influenza viruses. Using baloxavir resistance rates from prior clinical trials and the rate of influenza transmission observed in the study, the predicted number of PA/I38X transmission events was 4.8, assuming wild type and PA/I38X viruses were equally transmissible. However, no PA/I38X viruses were observed. These results suggest a low potential for baloxavir-resistant influenza virus transmission from treated to untreated individuals, potentially due to reduced viral/transmission fitness for PA/I38X viruses and/or low viral titres at the time when resistant viruses arise.
Keywords: antiviral agents; baloxavir; drug resistance; influenza; transmission; viral.
. 2023 Jan;17(1):e13079.
doi: 10.1111/irv.13079.
Investigating the transmission of baloxavir-resistant influenza viruses from treated index patients to untreated household contacts in the BLOCKSTONE study
Joanne Harding[SUP] 1 [/SUP], Corrado Bernasconi[SUP] 2 [/SUP], Sarah Williams[SUP] 1 [/SUP], Steffen Wildum[SUP] 2 [/SUP], Masahiro Kinoshita[SUP] 3 [/SUP], Takeki Uehara[SUP] 3 [/SUP], Aeron C Hurt[SUP] 2 [/SUP]
Affiliations
- PMID: 36702798
- DOI: 10.1111/irv.13079
Abstract
In a post-hoc analysis of the phase 3 BLOCKSTONE study (JapicCTI-184180), we investigated household transmission of baloxavir-resistant (PA/I38X) influenza viruses. Using baloxavir resistance rates from prior clinical trials and the rate of influenza transmission observed in the study, the predicted number of PA/I38X transmission events was 4.8, assuming wild type and PA/I38X viruses were equally transmissible. However, no PA/I38X viruses were observed. These results suggest a low potential for baloxavir-resistant influenza virus transmission from treated to untreated individuals, potentially due to reduced viral/transmission fitness for PA/I38X viruses and/or low viral titres at the time when resistant viruses arise.
Keywords: antiviral agents; baloxavir; drug resistance; influenza; transmission; viral.